
Loading, please wait...

Loading, please wait...

Understanding the nasolabial changes skeletal Class III patients experience is essential for achieving optimal aesthetic outcomes in maxillofacial surgery. Patients with skeletal Class III malocclusion often face significant midfacial depression. Surgeons typically address this issue using either Le Fort I maxillary advancement or paranasal Medpor implantation. Consequently, clinicians need precise comparative data to guide their choice between these two surgical interventions. A retrospective study recently compared these methods by analyzing twenty patients over a minimum six-month postoperative period.
The researchers used spiral CT data to measure linear segments, angles, volume, and curvature in the nasolabial region. Interestingly, both procedures successfully improved paranasal depression. However, the study identified significant differences in the subnasal and alar regions. For example, Medpor implantation resulted in much larger increases in alar width and alar base width. On the other hand, the Le Fort I advancement group showed a significant reduction in nasal length (N'-SN). This reduction did not occur in the implantation group, where nasal length remained stable.
In the subnasal region, Le Fort I advancement produced more pronounced changes in volume and curvature. Therefore, this technique remains the superior choice for patients requiring significant subnasal correction. Conversely, Medpor implantation provides an effective alternative for increasing paranasal volume with less impact on nasal length. Furthermore, surgeons must inform patients that Medpor may widen the nasal base more than advancement alone. These insights allow for more tailored surgical planning based on individual aesthetic needs and anatomical requirements.
Le Fort I advancement provides significantly greater changes in the subnasal region compared to Medpor implantation. It modifies subnasal volume and curvature more extensively than implants.
Yes, Medpor implantation causes a significantly greater increase in alar width and alar base width compared to Le Fort I advancement.
Le Fort I advancement often leads to a significant reduction in nasal length (N'-SN). In contrast, Medpor implantation typically shows no significant change in nasal length after the procedure.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Lv X et al. Comparison of nasolabial changes following Le Fort Ⅰ maxillary advancement versus Medpor implantation in skeletal class Ⅲ patients. Head Face Med. 2026 Apr 10. doi: 10.1186/s13005-026-00620-2. PMID: 41964092.
Vasudavan S, Jayaratne YS, Padwa BL. Nasolabial changes after Le Fort I advancement. J Oral Maxillofac Surg. 2012 Apr;70(4):e270-7. doi: 10.1016/j.joms.2011.11.026.
Paredes A et al. Three-dimensional analysis of nasolabial soft tissue changes after Le Fort I osteotomy: a systematic review of the literature. Int J Oral Maxillofac Surg. 2019 Oct;48(10):1330-1345. doi: 10.1016/j.ijom.2019.01.028.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study comparing nasolabial modifications after Le Fort I advancement and Medpor implantation for skeletal Class III patients to aid surgical planning....
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today